A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01019603
Recruitment Status : Completed
First Posted : November 25, 2009
Last Update Posted : June 23, 2017
Information provided by (Responsible Party):
GlaxoSmithKline ( Stiefel, a GSK Company )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : December 20, 2009
  Actual Study Completion Date : December 20, 2009
Michael Jarratt, Cary P Werner, & Alessandra B Alio Saenz. Relative bioavailability of tazarotenic acid when administered as tazarotene foam or tazarotene gel in subjects with moderate-to-severe acne vulgaris . Clinical Drug Investigation . 2013;33(4):283-289.